We need your help to support men and women who have been left with permanent sexual side effects after stopping antidepressants, finasteride (Propecia), or isotretinoin (Accutane).
raised of $100,000 target by 177 supporters in 24 countries
- Raise $100,000 which will be offered as a Prize to anyone who can produce a cure.
- Increase awareness among health professionals, researchers and the public.
- Build a network of healthcare professionals who engage with patients when they report persistent sexual side effects after discontinuing treatment.
- Get all of the medication labels changed to warn about the problem.
Where your money goes
Not a cent of any donation you make will go into overheads of any sort. RxISK’s involvement is entirely uncompensated and will remain so.
Every cent you donate will go into the Prize fund.
Most people are aware that antidepressants can cause sexual side effects but almost no-one knows these can endure permanently after treatment stops – sometimes only emerging after treatment stops. This a problem facing tens of thousands of people with:
- Post-SSRI Sexual Dysfunction (PSSD)
- Post-Finasteride Syndrome (PFS)
- Post-Retinoid Sexual Dysfunction (PRSD)
Finasteride is used in younger men for the treatment of male-pattern baldness. Isotretinoin is a retinoid used in the treatment of acne.
These conditions lead to suicide, relationship and family break-up, job loss and lead to a lot of wasted money taking risks on dangerous options held out as cures. At present there is almost no support for those affected.
The problems affect both men and women and cause genital numbness, pleasureless or weak orgasm, impotence, loss of sex drive and other difficulties. They can start after only a few days exposure to these medications and in some cases persist for decades.
We want to change this.
On September 12, 2017, we launched our campaign to raise $100,000 for a Prize which will be offered to anyone who finds a cure for PSSD, PFS or PRSD. This could be a doctor, a scientist, a drug company, a member of the public – anyone.
What You Can Do
See a list of those we’ve contacted
and find out how to get involvedPost-SSRI Sexual Dysfunction
Symptoms, diagnosis, published research, and more
In The Media
Media articles about PSSD and related sexual dysfunctionsPersonal Stories
Read personal stories from those affected by the conditions
RxISK was the first group to report on enduring sexual dysfunction after treatment with isotretinoin, in the peer-reviewed medical literature.
We were aware of common features between PSSD, PFS and PRSD from the beginning, and this is made clearer in our paper, Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases.
Help us to build a network of healthcare professionals who engage with patients when they report prescription drug side effects.
We believe this is important in getting better recognition of enduring sexual dysfunctions.
January 23, 2020. A history of antidepressants and sexual dysfunction including PSSD was published in the Journal of the Royal Society of Medicine.
December 12, 2019. New article: “Post-SSRI Sexual Dysfunction: A Bioelectric Mechanism?”
September 23, 2019. New paper about PSSD & other enduring sexual dysfunctions.
September 21, 2019. New paper about PSSD patient experiences.
June 11, 2019. EMA announces new warning.
October 27, 2018. RxISK submits petition to FDA about isotretinoin sexual side effects.
June 28, 2018. RxISK is mentioned in a U.S. News article about PSSD.
May 4, 2018. Two new publications.
January 18, 2018. Volunteer commissions textile artwork and raises £400.
November 4, 2017. Podcast on Mad in America.
You can read updates and related articles on our blog under the Prize category.
Help us to make a difference
We try to email everyone who donates. If you have donated and not been contacted, please let us know so we can establish where in the system your donation is.